Newsroom - Tevogen

Tevogen Details its Artificial Intelligence Initiative, Tevogen.AI; Proprietary AI-Powered Immunotherapy with Microsoft and Databricks Partnerships

View full press release

Tevogen Reaffirms Oncology Top-Line Revenue Forecast of $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $10 Billion and $14 Billion

View full press release

Tevogen Bio Announces Positive Proof-of-Concept Clinical Trial Results of Its Off-The-Shelf, Allogeneic Cytotoxic CD8+ T Cell Therapy for Treatment of Acute High-Risk COVID Patients, First Clinical Product of Company’s Precision Cell Therapy Platform

View full press release

Tevogen CEO Donates Shares to Support Education for Underprivileged Children

Tevogen Bio – December 22, 2025

Tevogen CEO Donates Personal Shares to Support Local Fire Department

Tevogen Bio – December 19, 2025

Tevogen CEO Supports Local Law Enforcement with Personal Contribution of 230,000 Company’s Shares of Common Stock

Tevogen Bio – December 11, 2025

Tevogen Celebrates Board Member Dr. Curtis Patton, Honored by Yale University for Distinguished Career and Lasting Contributions to Medical Education and Equity in Medicine

Tevogen Bio – December 9, 2025

Tevogen Recognized on 2025 NJBIZ Power List Amid Growth and Multi-Billion-Dollar Revenue Outlook

Tevogen Bio – December 8, 2025

Tevogen Highlights Continued Capital Efficiency Following Filing of Q3 2025 Form 10-Q

Tevogen Bio – November 14, 2025

Tevogen Reports Major Clinical Milestone: Expands HLA Coverage of its Investigational Precision T Cell Therapy for Acute and Long COVID

Tevogen Bio – November 5, 2025

Tevogen Clarifies Reported Financials, Highlighting Strong Capital Efficiency and Low Cash Burn

Tevogen Bio – November 3, 2025

Tevogen Senior Management Engages with Business and Community Leaders and Highlights Recent Progress

Tevogen Bio – October 29, 2025

Tevogen Updates on TVGN 489 Following Growing Long COVID Patient Interest

Tevogen Bio – October 15, 2025

Tevogen Marks Major Milestone in Its AI Initiative to Enhance Efficacy of T Cell–Based Therapies with 100x PredicTcell™ Beta Data Expansion

Tevogen Bio – September 25, 2025

Tevogen Highlights Potential Role of TVGN 489 in Eliminating Persistent Viral Reservoirs Linked to Long COVID

Tevogen Bio – September 23, 2025

Tevogen Commends HHS for Addressing Long COVID, Emphasizes TVGN 489’s Potential Impact for 20 Million Americans

Tevogen Bio – September 19, 2025

Tevogen CIO and Head of Tevogen.AI Mittul Mehta to Join Startup Forum Panel at Databricks DATA + AI World Tour in Boston

Tevogen Bio – September 10, 2025

Tevogen Estimates 5-Year Top-Line Revenue of ∼$6.5 Billion For Product Focused on Liver Cancer Prevention with High-Risk Chronic Hepatitis B Infection

Tevogen Bio – September 9, 2025

Tevogen Values TVGN 489 at $9–$11 Billion rNPV, Its First Clinical Product From the Proprietary ExacTcell™ Allogeneic T Cell Platform

Tevogen Bio – September 8, 2025

Tevogen Shares Valuation of Key Assets and Potential Forecast For Pipeline Product Focused on EBV Associated Leukemia and Lymphomas

Tevogen Bio – September 4, 2025

Tevogen Underscores the Importance of Precision Immunotherapies, Including TVGN 489 for Vulnerable Individuals Infected with SARS-CoV-2

Tevogen Bio – September 3, 2025

Tevogen Bio Highlights Proprietary Assets and Upcoming Valuation Disclosure

Tevogen Bio – August 27, 2025

Tevogen Expresses Gratitude to Yale for Recognition of Dr. Ryan Saadi and Company’s Mission of Health Equity

Tevogen Bio – August 26, 2025

Tevogen Sees Continued Growth in Institutional Ownership in Q2 2025; 72% of Holders Increased or Maintained Positions

Tevogen Bio – August 25, 2025

Tevogen Recognized in BINJE’s BEST Health Care 2025 for Advancing Health Equity and Sustainable Biopharma

Tevogen Bio – August 22, 2025

REPEAT – Tevogen Bio Enters Into Agreement for Up to $50 Million in Financing to Advance R&D and Clinical Development Efforts

Tevogen Bio – August 19, 2025

Tevogen Delivers Stronger Second Quarter and First Half 2025 Financial Results with Reduced Expenses and Growth Momentum

Tevogen Bio – August 19, 2025

Tevogen CEO Donates Personal Shares to Support Local Law Enforcement

Tevogen Bio – August 18, 2025

Tevogen CEO Donates Personal Shares to Support Brain Injury Recovery

Tevogen Bio – August 18, 2025

Tevogen to Release Internal Asset Valuation; CEO Affirms Assets Are Fully Protected

Tevogen Bio – August 14, 2025

REPEAT – Tevogen.AI Expands Collaboration With Databricks and Microsoft to Build the Beta Version of Its PredicTcell™ Model With a Focus on Oncology

Tevogen Bio – August 13, 2025

Tevogen Bio Reaffirms Investor Confidence with Estimated Asset Value Exceeding $10 Billion

Tevogen Bio – August 11, 2025

REPEAT – Tevogen Bio Specialty Care Reports Top-Line Revenue Forecast of Nearly $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $18 Billion and $22 Billion

Tevogen Bio – August 11, 2025

REPEAT – Tevogen Bio Oncology Reports Top-Line Revenue Forecast of $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $10 Billion and $14 Billion; Forecasts for Non-Oncology Therapeutic Areas to Follow

Tevogen Bio – August 11, 2025

REPEAT – Tevogen CEO Affirms Strong Growth, Capital Position, and AI Expansion in Letter to Stockholders

Tevogen Bio – August 11, 2025

REPEAT – Tevogen Sees Significant Institutional Ownership Growth; 73% of Holders Increase Positions

Tevogen Bio – August 8, 2025

Tevogen Receives $1 Million to Accelerate AI Driven Drug Discovery; Remains Well Capitalized to Execute Growth Strategy

Tevogen Bio – August 7, 2025

Tevogen Sees Significant Institutional Ownership Growth; 73% of Holders Increase Positions

Tevogen Bio – August 6, 2025

Tevogen.AI Expands Collaboration With Databricks and Microsoft to Build the Beta Version of Its PredicTcell™ Model With a Focus on Oncology

Tevogen Bio – August 5, 2025

Tevogen CEO Affirms Strong Growth, Capital Position, and AI Expansion in Letter to Stockholders

Tevogen Bio – August 1, 2025

Tevogen Bio to Accept $1 Million Additional Grant Funding for AI Expansion

Tevogen Bio – August 1, 2025

Tevogen Highlights 74% Insider Ownership, Reinforcing Long-Term Vision

Tevogen Bio – July 30, 2025

Tevogen.AI Applauds U.S. Government’s AI Action Plan; Reaffirms Commitment to Accelerating AI Innovation in Healthcare

Tevogen Bio – July 28, 2025

Tevogen.AI Receives International Patent Publication for AI Technology Predicting Immunologically Active Peptides

Tevogen Bio – July 18, 2025

Tevogen Signs Letter of Intent for New In-House Cell Therapy Manufacturing Facility

Tevogen Bio – July 17, 2025

Tevogen.AI Targets Faster Time-to-Market with AI-Powered Patient Matching Following PredicTcell Alpha Launch

Tevogen Bio – July 16, 2025

Tevogen.AI Builds Alpha Version of PredicTcell Model with Microsoft and Databricks; Observes Drastic Time Reduction in Target Analysis Translating to Potential Savings of Billions in Drug Development Costs

Tevogen Bio – July 14, 2025

Tevogen’s New Headquarters, Fully Funded by CEO, Centralizes R&D and AI Teams to Accelerate Innovation

Tevogen Bio – July 10, 2025

Tevogen CEO Contributes to Build-Out and First-Year Operations of New Headquarters

Tevogen Bio – June 30, 2025

Tevogen Updates on Development of EBV-Specific T Cell Therapy with Support from AI-Powered Target Discovery

Tevogen Bio – June 18, 2025

Tevogen Expands Headquarters Amid Growth of AI and Generics & Biosimilars Initiatives

Tevogen Bio – June 9, 2025

Tevogen Details its Artificial Intelligence Initiative, Tevogen.AI; Proprietary AI-Powered Immunotherapy with Microsoft and Databricks Partnerships

Tevogen Bio – May 30, 2025

Tevogen Bio Plans to Expand Specialty Care Pipeline to Include Patients 65+, Building on Previous Forecast of Nearly $1 Billion in Launch-Year; Updated rNPV to Follow

Tevogen Bio – May 23, 2025

Tevogen to Update on Robust Portfolio Assets, Business Expansion, Partnerships, Limited Tradable Float, High Insider Ownership and Strong Investor Confidence Ahead of June 23 Annual Meeting

Tevogen Bio – May 22, 2025

Tevogen Bio’s Business Model Addresses Biopharma Industry Challenges with Cost-Efficient Innovation

Tevogen Bio – May 12, 2025

Tevogen to Share Direct Registration System (DRS) Process Details Following Increased Shareholder Interest

Tevogen Bio – May 2, 2025

CD8 Technology Signs Letter of Intent for Tevogen Bio’s In-House Manufacturing Facility, Marking First Phase of Up to $50 Million Commitment

Tevogen Bio – April 30, 2025

Tevogen Informs Public Shareholders About DRS Accounts And Differences to Brokerage Accounts

Tevogen Bio – April 29, 2025

Tevogen CEO to Join Dialogue on Paths to Liquidity: Strategies for Adapting to a Volatile Market at BioNJ’s Fifteenth Annual Bio Partnering Conference with Experts from J.P. Morgan, RSM, and Cantor Fitzgerald

Tevogen Bio – April 29, 2025

Tevogen Reaffirms Oncology Top-Line Revenue Forecast of $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $10 Billion and $14 Billion

Tevogen Bio – April 28, 2025

Tevogen Bio Announces 2025 Annual Meeting

Tevogen Bio – April 25, 2025

Tevogen Bio Finalizes Agreement for Company’s Own Cell Therapy Production Facility

Tevogen Bio – April 17, 2025

Tevogen Bio Commissions Databricks to Accelerate Development of PredicTcell, a Precision AI Tool for Target Prediction

Tevogen Bio – April 15, 2025

Tevogen Bio – April 14, 2025

Tevogen Announces Tevogen Generics, a New Effort in Support of President Trump’s Initiative to Encourage Pharmaceutical Manufacturing in United States

Tevogen Bio – April 9, 2025

Tevogen Bio CIO and Head of Tevogen.AI Presented at AI x Bio Philly Event Showcasing Philly’s Leading AI Biotechs

Tevogen Bio – April 8, 2025

Tevogen Bio Highlights Most Recent Insider Ownership of 74%; Management Maintains Conviction in the Company’s Mission

Tevogen Bio – April 7, 2025

Tevogen Bio CEO Named to NJBIZ 2025 Health Care Power List as Company Advances Commercialization; Reaffirms Timeframe on Previously Announced Forecast

Tevogen Bio – March 26, 2025

Tevogen Bio Appoints David E. Banko as Global Head of Government Affairs and Patient Access, Advances Commercialization Plan

Tevogen Bio – March 25, 2025

Tevogen Bio Announces Unique T Cell Vaccine Under Development and Files Patent with the USPTO

Tevogen Bio – March 10, 2025

Tevogen Bio’s CIO & Head of Tevogen.AI, Mittul Mehta, Featured Speaker at Proskauer’s AI Discussion Panel

Tevogen Bio – March 7, 2025

Tevogen Bio to Receive $8 Million of Non-Dilutive Grant Funding, Reiterates Efficient Operations

Tevogen Bio – March 3, 2025

Tevogen Bio Founder and CEO Dr. Ryan Saadi Named to 2025 NJBIZ Power 100, Celebrating Innovation and Leadership in Accessible T Cell Therapy

Tevogen Bio – February 28, 2025

Tevogen Bio’s First Trading Year Efficiency: 600% Higher Market Cap Per Team Member, 79% Insider-Owned

Tevogen Bio – February 21, 2025

Tevogen Bio CEO Reinforces Commitment to Retention of Equity Capital and Long-Term Vision

Tevogen Bio – February 14, 2025

Tevogen Bio Shares 2024 Financing Activity on One Year Anniversary of Becoming a Publicly Listed Company; Highlights Operational Efficiency

Tevogen Bio – February 14, 2025

Tevogen Bio CEO Addresses Short Selling and Its Potential Impact on the Nation’s Health and Prosperity

Tevogen Bio – February 14, 2025

Tevogen Bio CEO Congratulates RFK Jr. on His Confirmation as Secretary of the HHS; Echoes Commitment to Innovation and Affordability for Americans

Tevogen Bio – February 13, 2025

Tevogen Bio’s Business Model Addresses Biopharma Industry Challenges with Cost-Efficient Innovation

Tevogen Bio – February 10, 2025

Tevogen Bio Meets BARDA TechWatch Team, Highlighting ExacTcell Technology’s Potential as a Scalable Medical Countermeasure

Tevogen Bio – February 7, 2025

Tevogen Bio Enters Agreement to Receive Up To $10 Million of Non-Dilutive Grant Funding

Tevogen Bio – January 28, 2025

Tevogen Bio CEO Congratulates Lynne Patton on Being Appointed Deputy Assistant to the President and Director of Minority Outreach

Tevogen Bio – January 27, 2025

Tevogen Bio Broadens Relationship with Microsoft to Deepen Artificial Intelligence Collaboration and Develop PredicTcell Technology on Azure

Tevogen Bio – January 24, 2025

Tevogen Bio Highlights the Future of AI-Driven Drug Development in Fireside Chat with Microsoft During the J.P. Morgan Healthcare Conference

Tevogen Bio – January 23, 2025

Tevogen Bio to Host Panel Discussions “AI In Biopharma: Next Frontier of Medical Innovation” and “Pioneering the Economics of Health: Balancing Access and Outcomes” During J.P. Morgan Healthcare Conference

Tevogen Bio – December 26th, 2024

Tevogen Bio to Host Panel “AI In Biopharma: Next Frontier of Medical Innovation” During the 43rd Annual J.P. Morgan Healthcare Conference

Tevogen Bio – December 23rd, 2024

Tevogen Bio Strengthens Robust IP Portfolio With Filing of Predictive AI Patent, With the Goal to Establish a Blueprint to Unlock the Full Potential of T Cell Therapies and Accelerate AI Integration to Advance Its Bold Growth Agenda

Tevogen Bio – December 19th, 2024

Tevogen Bio to Host Panel “Pioneering the Economics of Health: Balancing Access and Outcomes” During the 43rd Annual J.P. Morgan Healthcare Conference

Tevogen Bio – December 17th, 2024

Tevogen Bio to Attend the 43rd Annual J.P. Morgan Healthcare Conference

Tevogen Bio – December 10th, 2024

Dr. Ryan Saadi Commends Individuals Who Dedicate Time to Public Service, and Congratulates Mayor Victor Sordillo on His Induction Into the NJ League of Municipalities Hall of Fame

Tevogen Bio – December 5th, 2024

Tevogen Bio Prepares Organizational Readiness to Support Company’s Growth Strategy

Tevogen Bio – November 26th, 2024

Tevogen Bio CEO Reflects on Public Support, Reaffirms Preserving Shareholder Value Remains His Priority, and Reinforces Options Including a Potential Share Buyback to Support Company Value

Tevogen Bio – November 21st, 2024

Tevogen Bio Reports Third Quarter 2024 Financial Results; Highlights Significantly Improved Financial Position, Unreported Asset Value on Balance Sheets, Efficient Business Model

Tevogen Bio – November 19th, 2024

Tevogen Bio Nears Finalization of Agreement to Enhance R&D and Manufacturing Capabilities; $36 Million Line of Credit Available for Continued Operations

Tevogen Bio – November 8th, 2024

Tevogen Bio CEO Dr. Ryan Saadi Expresses Gratitude for Prestigious ROI-NJ Recognition, Highlighting Company’s Novel Business Model as Key to Sustainable Success through Patient Affordability

Tevogen Bio – November 5th, 2024

Tevogen Bio Leverages Microsoft Partnership to Deliver Machine Learning Based Target Identification to Address Human Papilloma Virus (HPV), Advancing TVGN 920

Tevogen Bio – November 5th, 2024

Tevogen Bio Announces Appointment of Anthony Tarantino as Patient Advocate to Enhance Community Engagement and Patient Support

Tevogen Bio – November 4th, 2024

Tevogen Bio Expands on Microsoft Partnership to Integrate Machine Learning and AI into Preclinical Processes, Accelerating Drug Development and Reducing Costs

Tevogen Bio – October 31st, 2024

Tevogen Bio Reports Nasdaq Listing Compliance as CEO Reaffirms His Commitment in Bridging the Information Gap About the Company

Tevogen Bio – October 29th, 2024

Tevogen Bio Signs Letter of Intent With CD8 Technology to Build Up to a $50 Million R&D and Manufacturing Facility; No Impact on Shareholder Equity

Tevogen Bio – October 29th, 2024

Tevogen Bio Provides Additional Guidance on Introduction of T Cell Therapy for Oncology and Specialty Care Therapeutic Areas

Tevogen Bio – October 25th, 2024

Tevogen Bio’s Effort in Artificial Intelligence, Tevogen AI, Joins Microsoft for Startups, Begins Accelerating drug Development

Tevogen Bio – October 23rd, 2024

Tevogen Bio To Provide Timelines Associated with Recently Announced Revenue Forecast and Updates on Operational Readiness This Week

Tevogen Bio – October 22nd, 2024

Tevogen Bio Specialty Care Reports Top-Line Revenue Forecast of Nearly $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $18 Billion and $22 Billion

Tevogen Bio – October 21st, 2024

Tevogen Bio Provides Clarity on CSO Share Sales to Satisfy Tax Obligations, Expects Additional Forecast and Progress Updates in the Coming Days

Tevogen Bio – October 21st, 2024

Tevogen CEO Expresses Gratitude for Unprecedented Public Support of Company’s Business Model of Commercial Success Through Patient Accessibility and Reaffirms His Commitment to Share Additional Details in the Coming Days

Tevogen Bio – October 18th, 2024

Tevogen Bio Oncology Reports Top-Line Revenue Forecast of $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $10 Billion and $14 Billion; Forecasts for Non-Oncology Therapeutic Areas to Follow

Tevogen Bio – October 17th, 2024

Tevogen Investors Congratulate on Prestigious Recognition of Pioneering Biopharma Business Model, Breakthrough Innovations, Building Assets Estimated to Exceed $10 Billion

Tevogen Bio – October 17th, 2024

Tevogen Bio Takes Lead in Developing Cell Therapies Designed to Eradicate Post Procedure Human Papilloma Virus in Women with Precancerous Cervical Lesions

Tevogen Bio – October 15th, 2024

Tevogen Bio Highlights the Publication of Promising Trial Data as the CEO Expresses Optimism About the Company’s Scientific Breakthrough in Mainstreaming Cell Therapy Through a New Class of Off-the-Shelf T-Cell Therapies, Manufactured and Stored for Immediate Use

Tevogen Bio – October 15th, 2024

Tevogen CEO Reaffirms the Company’s Commitment to Closing the Information Gap on Its Multi-Billion-Dollar Assets, Following the Release of Revenue Projections

Tevogen Bio – October 14th, 2024

Tevogen Bio Plans to Share $1B+ Revenue Potential of its Pipeline Portfolio Beginning Week of October 14, 2024

Tevogen Bio – October 11th, 2024

Tevogen Bio Extends Pipeline Prioritizing Oncology and Long COVID

Tevogen Bio – October 11th, 2024

Tevogen Bio Highlights Promising Trial Data as CEO Leads Patient Advocacy at Capitol Hill, Pledging to Leverage Multi-Billion Dollar Company Assets to Combat Long COVID and Spearhead a New Wave of Medical Innovation

Tevogen Bio – October 8th, 2024

Tevogen Bio Leadership Meets Members of U.S. Congress to Advocate for Long COVID Patients and Highlights Achievements and Assets as a Blueprint for Biotech Innovation

Tevogen Bio – September 24th, 2024

Tevogen Bio Secures $6 Million Series C Preferred Stock Investment

Tevogen Bio – August 22nd, 2024

Tevogen Bio Reports Second Quarter 2024 Financial Results, Eliminates Doubt About Company’s Ability to Continue as a Going Concern, Eliminates Series B Preferred Shares

Tevogen Bio – August 15th, 2024

Tevogen Bio’s Innovation and Public Health Advisory Board Chairperson, Professor Sten Vermund, Appointed Dean of the University of South Florida Health College of Public Health

Tevogen Bio – August 14th, 2024

Tevogen Bio’s Founding CEO, Ryan Saadi, Expresses Conviction in Company’s Growth Strategy and Reaffirms Newly Effective Form S-1 Does Not Relate to Previously Undisclosed New Issuance of Dilutive Securities

Tevogen Bio – August 11th, 2024

Tevogen Bio Issues Letter to Stockholders Highlighting Recent Achievements, Growth Plans, and Consideration of a Potential Share Buyback

Tevogen Bio – July 11th, 2024

Tevogen Bio’s R&D Leadership Discusses The Promise of Its Genetically Unmodified, Off-The-Shelf T Cell Technology For The Treatment of Infectious Diseases, Cancers, and Neurological Disorders With Nasdaq’s Kristina Ayanian

Tevogen Bio – July 10th, 2024

Tevogen Bio Seeks Advisor for Capital Raise Before Exploring Options for Lead Asset – CEO

Mergermarket – July 8th, 2024

Ryan Saadi Congratulates Marc Benioff on Receiving the Yale Legend in Leadership Award and Commends Yale School of Management for Recognizing the Importance of Integrating Corporate Success with Social Responsibility

Tevogen Bio – July 8th, 2024

Tevogen Bio Files Registration Statement for Previously Disclosed Securities; Does Not Relate to Any Previously Undisclosed New Issuances of Dilutive Securities

Tevogen Bio – June 26th, 2024

Tevogen Bio Announces Publication of Positive Phase I Clinical Trial Results for TVGN 489 in Blood Advances

Tevogen Bio – June 25th, 2024

Tevogen.AI Head Discusses Company’s Bold Strategy to Shape the Future of T Cell Therapies at Longwood Spring MIT Conference

Tevogen Bio – June 18th, 2024

Tevogen Bio Set to Join Russell 3000® Index

Tevogen Bio – June 12th, 2024

Tevogen Bio Enters Into Agreement for Up to $50 Million in Financing to Advance R&D and Clinical Development Efforts

Tevogen Bio – June 11th, 2024

Tevogen Bio Expresses Gratitude to Patients, First Responders, Elected Officials, and Members of the United States Congress for Attending Its Inaugural Post-Public Listing Social Engagement Event

Tevogen Bio – June 7th, 2024

Tevogen Bio Confirms Ongoing Efficacy of TVGN 489, Its Investigational Allogeneic Off-the-Shelf Immunotherapy, Against Dominant FLiRT Strains of SARS-CoV-2

Tevogen Bio – June 6th, 2024

Tevogen Bio Reports First Quarter 2024 Financial Results

Tevogen Bio – May 29th, 2024

Tevogen Bio Appoints Former Police Chief & FBI National Academy Graduate, William Keane, as Vice President of Strategic Initiatives

Tevogen Bio – May 16th, 2024

Tevogen Bio Announces Up to $50 Million in Financing to Further Advance Operational Objectives

Tevogen Bio – May 10th, 2024

Tevogen Bio Announces Full Year 2023 Financial Results and Upcoming Operational Objectives

Tevogen Bio – May 1st, 2024

Tevogen Bio CEO Highlights Expected Reporting of a $94.9 Million Liability Elimination, AI Initiative, and Leadership Appointments

Tevogen Bio – April 26th, 2024

Tevogen Bio’s Chief Scientific Officer Speaks on the Harnessing of Cytotoxic T Lymphocytes (CTLs) to Target Cancers

Tevogen Bio – April 11th, 2024

Tevogen Bio Appoints Tapan V Shah as Head of Investor Relations and Corporate Development

Tevogen Bio – April 3rd, 2024

Tevogen Bio Reports Series A-1 Preferred Stock Investment at $10 Conversion Price

Tevogen Bio – March 28th, 2024

Tevogen Bio Reports Its Investigational SARS-CoV-2 Specific T Cell Therapy, TVGN-489, Retains Activity Against the Dominant JN.1 Variant

Tevogen Bio – March 20th, 2024

Tevogen Bio Holdings Congratulates its Board Member and Esteemed Global Safety Management Expert, Victor Sordillo, on His appointment as Managing Director of Risk Advisory Services at Verita

Tevogen Bio – March 5th, 2024

Mittul Mehta, Head of Tevogen’s Artificial Intelligence Initiative Tevogen.ai, Emphasizes Importance of Proactive Talent Development for Biopharmaceutical Sector to Allow Rapid Adoption of AI

Tevogen Bio – February 27th, 2024

Cell Therapy Company Tevogen Bio Holdings Inc. Prepares to Launch Crucial Genetic Predisposition Study in Preparation to Investigate the Potential of TVGN 489 to Address Critical Unmet Need for Long COVID Treatment

Tevogen Bio – February 21st, 2024

Cell Therapy Company Tevogen Bio Holdings Inc. (Nasdaq: TVGN) Rings Opening Bell at Nasdaq Exchange on February 15th, 2024, Begins Public Trading on the Open Market

Tevogen Bio – February 17th, 2024

Tevogen Bio Announces $8 Million Equity Investment

Tevogen Bio – February 15th, 2024

Tevogen Bio Is Looking Forward to Closing Its Transaction With Semper Paratus

Tevogen Bio – January 31st, 2024

Tevogen Bio Appoints Globally Prominent Physicist Specializing in Space Biology, COVID-19, and AI Democratization, Afshin Beheshti, to Advisory Board

Tevogen Bio – January 29th, 2024

Semper Paratus Acquisition Corporation Announces Anticipated Listing of Tevogen Bio Holdings Inc. on Nasdaq

Tevogen Bio – January 24th, 2024

Tevogen Bio Inc. and Semper Paratus Acquisition Corporation Announce Effectiveness of Registration Statement for Business Combination

Tevogen Bio – January 5th, 2024

Tevogen Bio Expands Presence in Rapidly Emerging Field of Biotechnology AI: Files Patent Applications Related to AI-Driven T cell Target Identification and Receptor Engagement

Tevogen Bio – December 19th, 2023

Tevogen Bio Appoints IT Expert and Leader Mittul Mehta as Chief Information Officer and Head of Tevogen.ai Initiative

Tevogen Bio – October 23rd, 2023

Tevogen Bio Congratulates Innovation and Public Health Advisory Board Chairperson, Professor Sten Vermund on Being Elected to Serve as President of the Global Virus Network

Tevogen Bio – October 12th, 2023

Tevogen Bio Introduces Tevogen.ai to Enhance Patient Accessibility and Accelerate Innovation Leveraging Artificial Intelligence

Tevogen Bio – October 10th, 2023

Semper Paratus Acquisition Corporation Files Registration Statement on Form S-4 in Connection with Proposed Business Combination with Tevogen Bio Inc

Tevogen Bio – September 14th, 2023

Tevogen Bio Welcomes Victor Sordillo, Renowned Global Safety Management Expert, to its Board of Directors

Tevogen Bio – July 12th, 2023

Tevogen Bio to Become Publicly Listed on NYSE via Business Combination with Semper Paratus Acquisition Corporation

Tevogen Bio – June 29th, 2023

Tevogen Bio Expresses Gratitude as CEO is Named Recipient of Boy Scouts of America Distinguished Citizen Award

Tevogen Bio – May 11th, 2023

Tevogen Bio CSO to Discuss Investigational T Cell Therapy at NOLA Conference Focused on Long COVID and COVID-Related Cancer Risk, Alongside Leading Oncology Experts

Tevogen Bio – April 26th, 2023

Tevogen Bio Announces Positive Proof-of-Concept Clinical Trial Results of Its Off-The-Shelf, Allogeneic Cytotoxic CD8+ T Cell Therapy for Treatment of Acute High-Risk COVID Patients, First Clinical Product of Company’s Precision Cell Therapy Platform

Tevogen Bio – January 23rd, 2023

Tevogen Bio to Study its Investigational COVID-19 T Cell Therapy in Immunocompromised Patients Who are Unable to Benefit From Currently Available Prevention or Treatment Options

Tevogen Bio – December 7th, 2022

Tevogen Bio to Develop T Cell Therapies for Treatment of Epstein-Barr Virus Related Cancers and Multiple Sclerosis

Tevogen Bio – December 1st, 2022

Tevogen Bio to Study Therapeutic Potential of its Investigational COVID-19 T Cell Therapy in Long COVID

Tevogen Bio – November 22nd, 2022

Tevogen Bio CEO Dr. Ryan Saadi and Chief Scientific Officer Dr. Neal Flomenberg share White House concerns about emerging COVID-19 variants and their impact on immunocompromised patients, and express the company’s commitment to accelerate development of its investigational COVID-19 therapy

Tevogen Bio – October 27th, 2022

Tevogen Bio Expresses Gratitude for 2023 Nobel Peace Prize Nomination of the Company and its Founding CEO Ryan Saadi in Recognition of its Novel Business Model to Alleviate Health Inequality

Tevogen Bio – October 12th, 2022

Warren-based biotechnology company Tevogen Bio, CEO nominated for 2023 Nobel Peace Prize

ROI-NJ – October 6th, 2022

Tevogen Bio Appoints Esteemed Global Safety Management Expert Victor Sordillo to its Corporate Advisory Board

Tevogen Bio – August 31st, 2022

Tevogen Bio Appoints Three Prominent Healthcare Leaders to its Board of Directors

Tevogen Bio – August 17th, 2022

Tevogen Bio Announces Positive Safety Results Upon Completion of Patient Enrollment in Proof-of-Concept Clinical Trial of T cell Therapy for Elderly or High-Risk COVID-19 Patients

Tevogen Bio – August 1st, 2022

Tevogen Bio Appoints Acclaimed Oncologist and Immunotherapy Expert Neal Flomenberg, M.D. as Chief Scientific Officer and Global Head of R&D

Tevogen Bio – July 7th, 2022

Tevogen Bio Establishes Philadelphia R&D Center to Expedite Product Development in Oncology, Neurology, and Virology

Tevogen Bio – June 30th, 2022

Tevogen Bio Appoints Distinguished Clinician and Former Matheny President and CEO, Dr. Kendell R. Sprott, to Corporate Advisory Board

Tevogen Bio – June 23rd, 2022

Ryan Saadi’s Commencement Speech at Washington University of Science and Technology

Tevogen Bio – June 21st, 2022

Tevogen Bio Initiates Final Dose Level in Proof-of-Concept Clinical Trial of its Investigational T cell Therapy for High-Risk COVID-19 Patients

Tevogen Bio – June 7th, 2022

Tevogen Bio Expands Research and Development Capacity at CIC Philadelphia to Accommodate its Expanding Product Portfolio

Tevogen Bio – May 3rd, 2022

Tevogen Bio Expands Executive Leadership Team to Accelerate Operational Growth and Commercial Readiness

Tevogen Bio – April 5th, 2022

Tevogen Bio™ Appoints Prominent Industry Leader Susan Podlogar to the Company’s Corporate Advisory Board

Tevogen Bio – March 2nd, 2022

Tevogen Bio Accelerates Growth With New Corporate Hub to Accommodate its Expanding Operations

Tevogen Bio – February 7th, 2022

Tevogen Bio Announces Positive Safety Data from Second Cohort in Ongoing Proof-of-Concept Clinical Trial of TVGN-489, its Investigational T cell Therapy for Treatment of COVID-19 in High-Risk Patients

Tevogen Bio – February 3rd, 2022

SPH Dean’s next venture to drive down treatment costs

Yale Daily News – January 26th, 2022

Tevogen Bio to Study Potential Use of its T cell Technology in Epstein-Barr Virus and Multiple Sclerosis

Tevogen Bio – January 20th, 2022

Tevogen Bio Further Strengthens IP Portfolio With Additional Patent for Method of Preparing Its Investigational SARS-CoV-2 Specific T cell Therapy

Tevogen Bio – January 12th, 2022

Tevogen Bio Appoints Yale Public Health Dean Dr. Sten H. Vermund, Preeminent Global Expert in COVID-19 and Infectious Disease Epidemiology, to its Innovation and Public Health Advisory Council

Tevogen Bio – January 5th, 2022

Tevogen Bio Reinforces IP Portfolio With Additional US Patent for Its Investigational T Cell Therapy for Treatment of COVID-19

Businesswire – December 29th, 2021

Tevogen Bio Presents Data Detailing Immunologic Escape in SARS-CoV-2 Variants Underscoring Criticality of its T Cell Target Tuning Technology and Investigational COVID-19 therapy at ASH 2021

Businesswire – December 14th, 2021

Tevogen Bio Announces U.S. Patent and Trademark Office Has Granted Patent for Preparation of Tevogen’s SARS-CoV-2 Specific Allogeneic Cytotoxic T Lymphocytes (CTL) and Methods of Treatment Using Tevogen’s Investigational CTL Therapy for COVID-19

Businesswire – December 8th, 2021

Dr. Lindee Goh of Tapestry Networks and Jeffrey Feike, President and Chief Administrative Officer of Fort Loudoun Medical Center, Join Tevogen Bio’s Innovation and Public Health Advisory Council

Businesswire – December 6th, 2021

SHARED@Yale Roundtable Explores Health Care in the Era of COVID-19

Yale School of Public Health – December 6th, 2021

Tevogen Bio Announces its Investigational SARS-CoV-2 Specific T cell Therapy, TVGN-489, Is Not Affected by Omicron Variant Following Research Team Review of all Reported Mutations

Businesswire – December 2nd, 2021

FDA OK’s next phase for Jefferson University’s new COVID-19 treatment

6ABC News – November 29th, 2021

SHARED@Yale: Inaugural Roundtable on Post-COVID Health Care Announced

Yale School of Public Health – November 22nd, 2021

Tevogen Bio Announces First Cohort Dosed in Ongoing Proof of Concept Clinical Trial of TVGN-489, its Investigational T cell Immunotherapy Product for Treatment of COVID-19 in High-Risk Patients

Businesswire – November 16th, 2021

Tevogen Bio CEO Dr. Ryan Saadi Appointed to Yale School of Public Health Leadership Council

Businesswire – October 27th, 2021

A Pandemic Silver Lining: Why Now is our Opportunity to Disrupt the Flawed U.S. Health Care System

Yale School of Public Health – October 8th, 2021

Tevogen Bio Reaches Major Milestone in Commercial Manufacturing Readiness by Completing the Technology Transfer of its Investigational COVID-19 T Cell Therapy

Businesswire – September 9th, 2021

Tevogen Bio to Initiate Clinical Trial of its Investigational T Cell Therapy for COVID-19 at Thomas Jefferson University

Businesswire – September 1st, 2021

Tevogen Bio Revolutionizing Healthcare through an Innovative Public Health Centric Model

Pharma Tech Outlook – August 30th, 2021

Tevogen Bio Partners with Yale School of Public Health to Prepare Tomorrow’s Leaders in Regulatory Science

Businesswire – July 14th, 2021

Tevogen Bio Announces FDA Clearance of Investigational New Drug (IND) Application For its Cytotoxic T Cell Therapy for COVID-19

Businesswire – July 12th, 2021

Tevogen Bio’s TVGN-489, an Allogeneic SARS-CoV-2 Specific Cytotoxic T Cell Therapy, Demonstrates Strong Anti-Viral Activity in Preclinical Study, as Presented by Professor Neal Flomenberg of Thomas Jefferson University

Businesswire – May 11th, 2021

Tevogen Bio to Present Preclinical Data of TVGN-489, its Investigational Allogeneic Cytotoxic T Cell Therapy for COVID-19, at the 2021 Annual Meeting of American Association of Immunologists

Businesswire – April 12th, 2021

Tevogen CEO Ryan Saadi, MD, MPH, sat down with Cell & Gene Editor-In-Chief Erin Harris to discuss why T Cell therapy could be a potential game changer for COVID-19.

Cell & Gene – March 23rd, 2021

Tevogen Bio Announces Partnership With BioCentriq, New Jersey Innovation Institute’s Pioneering Cell and Gene Therapy Center, to Enhance Tevogen’s Development Capacity of Its Proprietary Targeted T Cell Therapy For COVID-19

Businesswire – March 15th, 2021

Tevogen Bio Secures Funding from Team of Doctors to Support Clinical Trials of Its Investigational Curative T Cell Therapy for COVID-19

Newswire – January 25th, 2021

Tevogen Bio Announces IND Submitted to FDA for Clinical Trials of T Cell Treatment for COVID-19

Newswire – October 14th, 2020

Dr. Flomenberg discusses T Cell therapy for COVID-19 with 6ABC News.

6ABC – August 20th, 2020

Tevogen Bio Announces Partnership With Preeminent Scientist Professor Neal Flomenberg, M.D., to Investigate Proprietary T-Cell Therapy for Treatment of COVID-19 & Influenza

Newswire – August 10th, 2020

Tevogen Bio Announces Steps Toward a Proprietary T Cell Therapy for Treatment of COVID-19 & Development of Bivalent Vaccine for COVID-19 & Influenza

Newswire – July 15th, 2020

Social Media

About Us

Leadership

Pipeline

Announcements

Get in Touch

New Jersey, USA

Careers Investors Cookies Settings Privacy Policy Terms of Use